Year: 2026
Type: article
Abstract: In recent years, with the gradual deepening of research, basic and clinical studies on targeted-immunotherapy combination regimens have flourished and yielded exciting results. The novel programmed cell death ligand 1 (PD-L1) inhibitor benmelstobart in combination with the targeted agent anlotinib demonstrates synergistic antitumor effects, achieving a synergy therapeutic outcome. This article focuses on the mechanisms underlying the combined action of "benmelstobart+anlotinib", summarizes the currently approved indications and clinical research progress, and aims to provide alternative therapeutic options for patients with malignant tumors as well as new insights for the development and selection of future combination treatment strategies.
Source: Frontiers in Oncology
Authors: Pan Cheng, Hong Gu, Qingqing Chen, Guangyu Zhao, Jichen He
Institutions: Yangzhou University, Jiangsu Province Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7154043892